C4 Therapeutics Inc (CCCC)vsJohnson & Johnson (JNJ)
CCCC
C4 Therapeutics Inc
$3.52
-0.85%
HEALTHCARE · Cap: $403.57M
JNJ
Johnson & Johnson
$255.88
-3.66%
HEALTHCARE · Cap: $615.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 280813% more annual revenue ($97.93B vs $34.86M). JNJ leads profitability with a 21.5% profit margin vs -297.8%. JNJ earns a higher WallStSmart Score of 57/100 (C).
CCCC
Avoid26
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+72.5%
Fair Value
$6.65
Current Price
$3.52
$3.13 discount
Intrinsic value data unavailable for JNJ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -44.3% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CCCC
The strongest argument for CCCC centers on Debt/Equity, Price/Book.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bear Case : CCCC
The primary concerns for CCCC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CCCC profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
CCCC carries more volatility with a beta of 2.91 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 26/100), backed by strong 21.5% margins. CCCC offers better value entry with a 72.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
C4 Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?